Human-in-the-loop is the compliance bridge for AI in pharma

Every consequential AI output in a GxP environment requires a qualified human reviewer. The AI assists by surfacing information, drafting analyses, or flagging deviations; the human decides and signs. This is not a limitation of the technology; it is a regulatory expectation and a sound risk management practice.

The pattern maps to existing notes on supervised agents (see: agents need human confirmation for consequential actions), but in pharma the stakes are higher: a wrong batch release decision can harm patients. The human reviewer’s approval is the electronic signature under Part 11; the AI’s output is the supporting evidence. The reviewer must understand the AI’s reasoning, its confidence level, and its known failure modes. This is why observability and structured outputs matter in regulated settings more than anywhere else.